Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 5, 2018

Update in diagnosis and management of primary aldosteronism: reply to a Letter to the Editor

  • Sofia Michele Dick , Marina Queiroz , Letícia Almeida Brondani , Angélica Dall’Agnol , Bárbara Luisa Bernardi and Sandra Pinho Silveiro EMAIL logo
  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Gay A. Letter to the Editor relative to Clin Chem Lab Med 2018;56(3):360–372. Clin Chem Lab Med 2018;56:e251–2.10.1515/cclm-2018-0245Search in Google Scholar PubMed

2. Dick SM, Queiroz M, Bernardi BL, Dall’Agnol A, Brondani LA, Silveiro SP. Update in diagnosis and management of primary aldosteronism. Clin Chem Lab Med 2018;56:360–72.10.1515/cclm-2017-0217Search in Google Scholar PubMed

3. Gromotowicz-Poplawska A, Szoka P, Kolodziejczyk P, Kramkowski K, Wojewodzka-Zelezniakowicz M, Chabielska E. New agents modulating the renin-angiotensin-aldosterone system – will there be a new therapeutic option? Exp Biol Med (Maywood) 2016;241:1888–99.10.1177/1535370216660211Search in Google Scholar PubMed PubMed Central

4. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, doubleblind trial. Eur Heart J 2013;34:2453–63.10.1093/eurheartj/eht187Search in Google Scholar PubMed PubMed Central

5. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016;37:2105–14.10.1093/eurheartj/ehw132Search in Google Scholar PubMed PubMed Central

6. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem Med Chem 2012;7:1385–403.10.1002/cmdc.201200081Search in Google Scholar PubMed

7. Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail 2016;18:28–37.10.1002/ejhf.444Search in Google Scholar PubMed

8. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014;64:69–78.10.1097/FJC.0000000000000091Search in Google Scholar PubMed

Received: 2018-03-26
Accepted: 2018-03-29
Published Online: 2018-05-05
Published in Print: 2018-10-25

©2018 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 24.2.2024 from
Scroll to top button